Covid treatments

Home>Tag: Covid treatments
Jan 12 2021

Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article

By |2021-01-11T19:57:47-05:00January 12th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: "HALB") was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021.  Halberd was noted to be working in a different direction from the vaccine producers.  ...

Dec 17 2020

Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19

By |2020-12-16T20:11:40-05:00December 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19.  Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month.  The procedure is ...

Nov 19 2020

Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation

By |2020-11-18T19:10:48-05:00November 19th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood.  By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...

Sep 14 2020

Halberd Corporation Outlines Multi-Phase $1.4 M Covid-19 Program in Partnership With ASU

By |2020-09-13T20:36:48-04:00September 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 14, 2020 – Halberd Corporation (OTC PINK: "HALB") today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University. The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based ...

Sep 8 2020

Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU

By |2020-09-08T11:19:17-04:00September 8th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of ...

Sep 2 2020

Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities

By |2020-09-02T08:00:19-04:00September 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services ...

Aug 31 2020

Halberd Selects Arizona State University (ASU) to Develop Its Patented Covid-19 Treatment(s)

By |2020-08-31T08:00:31-04:00August 31st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 31, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.  The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications ...

Go to Top